New Roche Deal Targets B7H3 Tumors Worldwide

Roche secures global rights to MediLink’s YL201 ADC, expanding its oncology pipeline and deepening cross-border biotech partnerships

10 Mar 2026

Roche is doubling down on antibody drug conjugates with a deal that could reach $570 million, licensing a next generation cancer therapy from Chinese biotech MediLink. The agreement marks one of the largest ADC partnerships announced in 2026 and highlights the growing global competition to develop more precise oncology treatments.

Announced on January 8, the deal gives Roche exclusive worldwide rights to develop, manufacture, and commercialize YL201, an experimental therapy designed to target B7H3. The immune checkpoint protein is widely found across several aggressive solid tumors, making it an increasingly attractive target for drug developers. MediLink will keep commercial rights in mainland China, Hong Kong, and Macau, where YL201 has already moved into registrational Phase 2 trials for small cell lung cancer and nasopharyngeal carcinoma. Early clinical results suggest encouraging response rates and potential survival gains in second line patients.

A key element of the program is MediLink’s TMALIN platform, a tumor microenvironment activated linker technology. The system is designed to release a potent camptothecin based payload mainly inside tumor tissue rather than throughout the body. By concentrating the drug where it is needed most, researchers hope to deliver strong anti tumor activity while limiting systemic toxicity, a challenge that has drawn increasing scrutiny in the ADC field.

The partnership also builds on an existing relationship between the companies. Roche first teamed up with MediLink in early 2024 in a deal that could reach $1 billion for YL211, a c Met targeting ADC for solid tumors. YL201 now marks the third straight year Roche has opened the calendar with a major Chinese ADC licensing agreement, signaling a clear strategy to expand its oncology pipeline through cross border partnerships.

The timing is notable. Biopharma licensing deals have surged in value in early 2026, with average deal sizes reaching about $1.3 billion, roughly three quarters higher than the previous year. As the science behind ADCs advances, partnerships like this are increasingly shaping the next wave of precision cancer therapy.